What pharmacologic therapy is appropriate for a 68-year-old woman with hypertension, hyperlipidemia, obesity (BMI 30), taking estradiol and losartan‑hydrochlorothiazide, who presents with insomnia characterized by frequent nocturnal awakenings?

Pharmacologic Treatment Recommendation for Sleep Maintenance Insomnia

For this 68-year-old woman with sleep maintenance insomnia (frequent nocturnal awakenings), I recommend either low-dose doxepin (3-6 mg) or suvorexant as first-line pharmacologic options, with a slight preference for doxepin given the favorable safety profile in older adults and specific efficacy for sleep maintenance problems. 1

Rationale Based on Clinical Presentation

This patient has sleep maintenance insomnia (waking 4-5 times nightly), not sleep onset insomnia. This distinction is critical because different medications target different insomnia subtypes. The American Academy of Sleep Medicine 2017 guidelines specifically identify which agents work for sleep maintenance versus sleep onset. 1

Evidence-Based Options for Sleep Maintenance Insomnia

According to AASM guidelines, the following medications have evidence for sleep maintenance insomnia 1:

Primary Options:

• Doxepin (3-6 mg): Specifically recommended for sleep maintenance insomnia
• Suvorexant (10-20 mg): Orexin receptor antagonist for sleep maintenance
• Eszopiclone (2-3 mg): Effective for both sleep onset AND maintenance
• Zolpidem (10 mg): Effective for both sleep onset AND maintenance
• Temazepam (15 mg): Effective for both sleep onset AND maintenance

Why Doxepin or Suvorexant Are Preferred Here

Doxepin advantages:

• At low doses (3-6 mg), it has minimal anticholinergic effects compared to higher antidepressant doses
• Specifically targets sleep maintenance without significant next-day sedation
• No abuse potential or withdrawal concerns
• Well-studied in older adults

Suvorexant advantages:

• Works by inhibiting wakefulness rather than inducing sedation—a mechanistically different approach 2, 3
• No evidence of rebound insomnia or withdrawal 2
• Little to no abuse potential 2
• Newer evidence suggests sustained efficacy over 12 months 3

Important Safety Considerations in This Patient

Age-Related Concerns (68 years old)

Older adults have increased sensitivity to sedative-hypnotics and higher risk of:

• Falls and fractures
• Cognitive impairment
• Next-day sedation
• Complex sleep behaviors

Critical dosing adjustments needed:

• If using zolpidem: Must use 5 mg (not 10 mg) in women and older adults per FDA guidance 4
• Benzodiazepines (temazepam, triazolam) carry higher fall risk and should be avoided if possible in this age group
• Eszopiclone may cause next-day impairment at 3 mg doses

Drug Interaction Check

Her current losartan-HCTZ 100-25 mg is not contraindicated with any of the recommended sleep medications. 5 However, note that she's on a high dose of HCTZ (25 mg), which could theoretically contribute to nocturia and nocturnal awakenings—worth exploring if she's waking to urinate.

Medications to AVOID

The AASM guidelines explicitly recommend against the following 1:

• Trazodone: Despite widespread off-label use, evidence does not support efficacy
• Diphenhydramine (Benadryl): Not recommended; anticholinergic burden in elderly
• Melatonin (2 mg): Insufficient evidence for chronic insomnia treatment
• Tiagabine: Not recommended

Practical Prescribing Algorithm

Step 1: Start with doxepin 3 mg at bedtime

• Lowest effective dose for sleep maintenance
• Take 30 minutes before bed
• Can increase to 6 mg if inadequate response after 1-2 weeks

Alternative Step 1: Suvorexant 10 mg at bedtime

• Take within 30 minutes of bedtime with at least 7 hours remaining before planned awakening
• Can increase to 20 mg if needed
• More expensive but favorable safety profile

Step 2: If inadequate response after 2-4 weeks

• Consider eszopiclone 2 mg (not 3 mg given age)
• Or switch to alternative first-line agent

Step 3: Reassess after 4-8 weeks

• Evaluate for continued need
• Consider tapering if sleep has normalized
• Screen for underlying sleep disorders (sleep apnea given BMI 30)

Critical Pitfalls to Avoid

1. Don't prescribe zaleplon, triazolam, or ramelteon—these are for sleep onset only, not maintenance 1

2. Screen for obstructive sleep apnea (OSA): BMI 30 is a red flag. Frequent awakenings could be from OSA, not primary insomnia. If OSA suspected, obtain sleep study before treating with sedatives.

3. Don't use standard zolpidem 10 mg dose: FDA mandates lower dosing (5 mg) in women and elderly due to next-day impairment and driving risk 4

4. Avoid chronic benzodiazepine use: While temazepam has evidence, the 2016 ACP review noted observational data linking hypnotics to increased dementia, fractures, and major injury risk 4

5. Set clear expectations: All AASM recommendations are "WEAK" strength, meaning benefits outweigh harms but individual patient factors matter 1. Discuss realistic goals (improvement, not perfection) and time-limited use.

6. Address the estradiol: At age 68, continued estradiol use should be questioned—menopausal hormone therapy is typically discontinued by this age due to cardiovascular and cancer risks. This may be contributing to sleep issues.

Monitoring Plan

• Follow up in 2-4 weeks to assess efficacy and adverse effects
• Specifically ask about next-day sedation, falls, confusion, or complex sleep behaviors
• Reassess need for continued therapy at 3 months
• Consider cognitive behavioral therapy for insomnia (CBT-I) as adjunct or alternative if available 6, 7